The new facility will create 250 jobs for the country, according to GSK CEO Andrew Witty. The company has already employed over 8,500 people in India. Right now, the lead site is set to be in Bangalore, but the location has yet to be set in stone and finalized.
The company said the factory will make medical and pharmaceutical products for the Indian market at a rate of 8 billion tablets and 1 billion capsules per year, and will be the second facility manufacturing these types of products for GlaxoSmithKline in India.
GSK spokespeople have said that the facility is expected to be operation sometime in 2017 and will also include a warehouse, site infrastructure and utilities.
The company has most recently worked specifically with prescription drugs and vaccines, but it is expanding its manufacturing capacity in India to “advance its portfolio” of products related to gastroenterology and anti-inflammatory drugs, such as for swollen joints.
GSK released a statement from Witty, saying “GSK is a long standing investor in India and we fully support the government in their efforts to increase access to medicines and better healthcare that is affordable for their citizens.”
About David Pulman
David Pulman GSK (http://www.forbes.com/profile/david-pulman/) is responsible for Global Manufacturing and Supply organization Global Procurement. He joined Glaxo in 1978 and has since gained broad experiences with manufacturing operations. Visit the website to learn more about David Pulman and his company.
Distributed by Iterate LLC
Company Name:David Pulman
Contact Person: David Pulman
Email:media@vytalnet.com
Phone: 4157669098
City: San Francisco
State: CA
Country: United States
Website: http://www.forbes.com/profile/david-pulman/
0 comments:
Post a Comment